Bal Pharma Limited (BALPHARMA.BO)
INR 120.0
(-0.87%)
INR 120.0
(-0.87%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 71.68 Million | -18.43 Million | 267.95 Million | 223.35 Million | 232.43 Million | 77.57 Million |
| Net Income | 73.92 Million | 47.48 Million | 91.82 Million | 41.02 Million | -135.29 Million | -2.02 Million |
| Depreciation & Amortization | 100.71 Million | 91.28 Million | 90.4 Million | 95.21 Million | 2.23 Million | 61.55 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -40.42 Million | -275.25 Million | 16.6 Million | -27.99 Million | 179.37 Million | -70.69 Million |
| Other non-cash items | 185.84 Million | 118.04 Million | 69.12 Million | 115.1 Million | 186.11 Million | 88.74 Million |
| Investing Cash Flow | -195.79 Million | -221.82 Million | -94.84 Million | -55.34 Million | -47.05 Million | -80.43 Million |
| Investments in PPE | -109.8 Million | -146.45 Million | -84.69 Million | -33.64 Million | -50.63 Million | -85.94 Million |
| Acquisitions | 119 Thousand | -68.66 Million | - | -9.79 Million | 184 Thousand | 184 Thousand |
| Investment purchases | -86.11 Million | -8.1 Million | -11.94 Million | -9.11 Million | - | - |
| Sales/Maturities of investments | - | 1.4 Million | - | -3.08 Million | - | - |
| Other Investing Activities | -79.1 Million | -1000.00 | 1.78 Million | 281 Thousand | 3.39 Million | 5.32 Million |
| Financing Cash Flow | 151.2 Million | 244 Million | -172.21 Million | -166.32 Million | -199.73 Million | 136 Thousand |
| Debt repayment | -161.87 Million | -354.17 Million | -62.48 Million | -36.63 Million | -87.96 Million | -138.33 Million |
| Dividends payments | -15.69 Million | -15.57 Million | -14.82 Million | -2.91 Million | -14.17 Million | -14.72 Million |
| Common Stock Repurchased | - | -138.56 Million | -104.03 Million | -205.73 Million | - | - |
| Common Stock Issuance | 12.28 Million | 39.17 Million | 9.12 Million | 41.87 Million | - | - |
| Other Financing Activities | -7.26 Million | 713.14 Million | 1000.00 | 37.08 Million | -97.59 Million | 153.18 Million |
| Accounts receivables | -142.93 Million | -398.42 Million | -101.87 Million | -185 Million | 134.67 Million | 4.86 Million |
| Accounts payables | -5.95 Million | 269.05 Million | 203.19 Million | 89.8 Million | -87.52 Million | -26.19 Million |
| Inventory | 101.93 Million | -236.09 Million | -140.1 Million | 73.26 Million | 20.39 Million | -32.57 Million |
| Other working capital | 6.51 Million | 90.21 Million | 55.39 Million | -6.05 Million | 111.82 Million | -16.78 Million |
| Cash at beginning of period | 16.36 Million | 11.12 Million | 10.23 Million | 8.58 Million | 24.36 Million | 27.08 Million |
| Cash at end of period | 132.92 Million | 14.87 Million | 11.12 Million | 10.23 Million | 8.58 Million | 24.36 Million |
| Capital Expenditure | -109.8 Million | -146.45 Million | -84.69 Million | -33.64 Million | -50.63 Million | -85.94 Million |
| Effect of forex changes on cash | - | 1000.00 | -1000.00 | -36 Thousand | -1.42 Million | -2000.00 |
| Net cash flow / Change in cash | 116.55 Million | 3.74 Million | 891 Thousand | 1.64 Million | -15.77 Million | -2.72 Million |
| Free Cash Flow | -38.11 Million | -164.88 Million | 183.26 Million | 189.7 Million | 181.8 Million | -8.36 Million |
| Breakdown | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 73.92 Million | 8.88 Million | 9.45 Million | 843 Thousand | 47.48 Million | 16 Million |
| Depreciation & Amortization | 100.71 Million | 29.62 Million | 24.19 Million | 25.34 Million | 91.28 Million | 20.86 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -40.42 Million | - | - | - | -275.25 Million | - |
| Other non-cash items | 185.84 Million | 20.73 Million | -24.19 Million | -25.34 Million | 118.04 Million | -20.86 Million |
| Investing Cash Flow | -195.79 Million | - | - | - | -221.82 Million | - |
| Investments in PPE | -109.8 Million | - | - | - | -146.45 Million | - |
| Acquisitions | 119 Thousand | - | - | - | -68.66 Million | - |
| Investment purchases | -86.11 Million | - | - | - | -8.1 Million | - |
| Sales/Maturities of investments | - | - | - | - | 1.4 Million | - |
| Other Investing Activities | - | - | - | - | -1000.00 | - |
| Financing Cash Flow | 151.2 Million | - | - | - | 244 Million | - |
| Debt repayment | -161.87 Million | - | - | - | -354.17 Million | - |
| Dividends payments | -15.69 Million | - | - | - | -15.57 Million | - |
| Common Stock Repurchased | - | - | - | - | -138.56 Million | - |
| Common Stock Issuance | 12.28 Million | - | - | - | 39.17 Million | - |
| Other Financing Activities | -7.26 Million | - | - | - | 713.14 Million | - |
| Accounts receivables | -142.93 Million | - | - | - | -398.42 Million | - |
| Accounts payables | -5.95 Million | - | - | - | 269.05 Million | - |
| Inventory | 101.93 Million | - | - | - | -236.09 Million | - |
| Other working capital | 6.51 Million | - | - | - | 90.21 Million | - |
| Cash at beginning of period | 16.36 Million | 83.79 Million | 74.33 Million | 16.36 Million | 11.12 Million | 359 Thousand |
| Cash at end of period | 132.92 Million | 143.04 Million | 83.79 Million | 843 Thousand | 14.87 Million | 16.36 Million |
| Capital Expenditure | -109.8 Million | - | - | - | -146.45 Million | - |
| Effect of forex changes on cash | - | - | - | - | 1000.00 | - |
| Net cash flow / Change in cash | 116.55 Million | 59.25 Million | 9.45 Million | -15.52 Million | 3.74 Million | 16 Million |
| Free Cash Flow | -38.11 Million | 59.25 Million | 9.45 Million | 843 Thousand | -164.88 Million | 16 Million |
DII-B
PDS
HYPMY
HDYNQ
FSTR
TOP-R